...
anab-img

AnaptysBio Inc, Common Stock

ANAB

NSQ

$16.65

+$1.06

(6.8%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$474.38M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
686.93K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
-0.24
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$14.2 L
$41.31 H
$16.65

About AnaptysBio Inc, Common Stock

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameANABSectorS&P500
1-Week Return-27.23%-3.72%-0.05%
1-Month Return-11.81%-1.85%2.75%
3-Month Return-57%-11.4%7.4%
6-Month Return-28.79%-4.41%10.47%
1-Year Return-15.27%4.13%27.57%
3-Year Return-52.85%0.3%29.56%
5-Year Return1.52%36.62%89.3%
10-Year Return-2.06%106.81%206.09%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue8.00M75.00M63.17M10.29M17.16M[{"date":"2019-12-31","value":10.67,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":84.23,"profit":true},{"date":"2022-12-31","value":13.72,"profit":true},{"date":"2023-12-31","value":22.88,"profit":true}]
Cost of Revenue99.34M80.03M98.50M2.33M2.38M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":80.56,"profit":true},{"date":"2021-12-31","value":99.15,"profit":true},{"date":"2022-12-31","value":2.35,"profit":true},{"date":"2023-12-31","value":2.39,"profit":true}]
Gross Profit(91.34M)(5.03M)(35.32M)7.95M14.78M[{"date":"2019-12-31","value":-617.94,"profit":false},{"date":"2020-12-31","value":-34,"profit":false},{"date":"2021-12-31","value":-238.96,"profit":false},{"date":"2022-12-31","value":53.8,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin(1141.72%)(6.70%)(55.91%)77.30%86.15%[{"date":"2019-12-31","value":-1325.25,"profit":false},{"date":"2020-12-31","value":-7.78,"profit":false},{"date":"2021-12-31","value":-64.9,"profit":false},{"date":"2022-12-31","value":89.73,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses115.43M98.88M119.99M125.44M181.57M[{"date":"2019-12-31","value":63.58,"profit":true},{"date":"2020-12-31","value":54.46,"profit":true},{"date":"2021-12-31","value":66.08,"profit":true},{"date":"2022-12-31","value":69.09,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(107.43M)(23.88M)(56.81M)(115.15M)(164.41M)[{"date":"2019-12-31","value":-10743200000,"profit":false},{"date":"2020-12-31","value":-2387900000,"profit":false},{"date":"2021-12-31","value":-5681400000,"profit":false},{"date":"2022-12-31","value":-11515400000,"profit":false},{"date":"2023-12-31","value":-16441100000,"profit":false}]
Total Non-Operating Income/Expense19.89M7.91M(2.00M)(27.10M)1.24M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":39.76,"profit":true},{"date":"2021-12-31","value":-10.06,"profit":false},{"date":"2022-12-31","value":-136.29,"profit":false},{"date":"2023-12-31","value":6.26,"profit":true}]
Pre-Tax Income(97.49M)(19.93M)(57.80M)(128.70M)(163.62M)[{"date":"2019-12-31","value":-9748800000,"profit":false},{"date":"2020-12-31","value":-1993100000,"profit":false},{"date":"2021-12-31","value":-5779600000,"profit":false},{"date":"2022-12-31","value":-12870000000,"profit":false},{"date":"2023-12-31","value":-16362300000,"profit":false}]
Income Taxes(152.00K)(11.00K)(603.00K)24.00K(4.00K)[{"date":"2019-12-31","value":-633.33,"profit":false},{"date":"2020-12-31","value":-45.83,"profit":false},{"date":"2021-12-31","value":-2512.5,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-16.67,"profit":false}]
Income After Taxes(97.34M)(19.92M)(57.19M)(128.72M)(163.62M)[{"date":"2019-12-31","value":-9733600000,"profit":false},{"date":"2020-12-31","value":-1992000000,"profit":false},{"date":"2021-12-31","value":-5719300000,"profit":false},{"date":"2022-12-31","value":-12872400000,"profit":false},{"date":"2023-12-31","value":-16361900000,"profit":false}]
Income From Continuous Operations(97.34M)(19.93M)(57.80M)(128.72M)(147.82M)[{"date":"2019-12-31","value":-9733600000,"profit":false},{"date":"2020-12-31","value":-1993100000,"profit":false},{"date":"2021-12-31","value":-5779600000,"profit":false},{"date":"2022-12-31","value":-12872400000,"profit":false},{"date":"2023-12-31","value":-14782100000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(97.34M)(19.92M)(57.19M)(128.72M)(163.62M)[{"date":"2019-12-31","value":-9733600000,"profit":false},{"date":"2020-12-31","value":-1992000000,"profit":false},{"date":"2021-12-31","value":-5719300000,"profit":false},{"date":"2022-12-31","value":-12872400000,"profit":false},{"date":"2023-12-31","value":-16361900000,"profit":false}]
EPS (Diluted)(3.61)(0.76)(2.05)(4.57)(6.08)[{"date":"2019-12-31","value":-361,"profit":false},{"date":"2020-12-31","value":-76,"profit":false},{"date":"2021-12-31","value":-205,"profit":false},{"date":"2022-12-31","value":-457,"profit":false},{"date":"2023-12-31","value":-608,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ANAB
Cash Ratio 9.80
Current Ratio 10.23
Quick Ratio 10.50

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ANAB
ROA (LTM) -17.85%
ROE (LTM) -161.82%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ANAB
Debt Ratio Lower is generally better. Negative is bad. 0.83
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.17

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ANAB
Trailing PE NM
Forward PE NM
P/S (TTM) 8.30
P/B 5.62
Price/FCF NM
EV/R 1.06
EV/Ebitda NM
PEG NM

FAQs

What is AnaptysBio Inc share price today?

AnaptysBio Inc (ANAB) share price today is $16.65

Can Indians buy AnaptysBio Inc shares?

Yes, Indians can buy shares of AnaptysBio Inc (ANAB) on Vested. To buy AnaptysBio Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ANAB stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of AnaptysBio Inc be purchased?

Yes, you can purchase fractional shares of AnaptysBio Inc (ANAB) via the Vested app. You can start investing in AnaptysBio Inc (ANAB) with a minimum investment of $1.

How to invest in AnaptysBio Inc shares from India?

You can invest in shares of AnaptysBio Inc (ANAB) via Vested in three simple steps:

  • Click on Sign Up or Invest in ANAB stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in AnaptysBio Inc shares
What is AnaptysBio Inc 52-week high and low stock price?

The 52-week high price of AnaptysBio Inc (ANAB) is $41.31. The 52-week low price of AnaptysBio Inc (ANAB) is $14.2.

What is AnaptysBio Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of AnaptysBio Inc (ANAB) is

What is AnaptysBio Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of AnaptysBio Inc (ANAB) is 5.62

What is AnaptysBio Inc dividend yield?

The dividend yield of AnaptysBio Inc (ANAB) is 0.00%

What is the Market Cap of AnaptysBio Inc?

The market capitalization of AnaptysBio Inc (ANAB) is $474.38M

What is AnaptysBio Inc’s stock symbol?

The stock symbol (or ticker) of AnaptysBio Inc is ANAB

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top